Using viral load, CD4+ levels, and clinical response to guide antiviral therapy for HIV

Cleveland Clinic Journal of Medicine

Volumn 67, Issue 5, 2000, Pages 321-328

  Calabrese, Leonard H ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ARTICLE; BLOOD; CD4 LYMPHOCYTE COUNT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PRACTICE GUIDELINE; TREATMENT FAILURE; VIROLOGY; VIRUS LOAD;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HUMANS; PRACTICE GUIDELINES; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 0034185706     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.67.5.321     Document Type: Article

References (18)

1. Carpenter C, Cooper D, Fischel M, et al. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society - USA panel. JAMA 2000; 283:381-390.
2. Guidelines for the use of antiretroviral agents in adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. January 28, 2000. http://www.hivatis.org.
3. Raboud JM, Montaner JS, Conway B, et al. Suppression of plasma viral load below 20 copies/mL is required to achieve a longterm response to therapy. AIDS 1998; 12:1619-1624.
4. Henry K. The case for more cautious patient focused antiretroviral therapy. Ann Intern Med 2000; 132:306-311.
5. + T cell responses associated with control of viremia. Science 1997; 278:1447-1450.
6. Bucy RP, Rockett RD, Derdeyn CA, et al. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999; 103:1391-1398.
7. Autran B, Carcelain G, Tubiana R, et al. Effects of antiretroviral therapy on immune reconstitution [abstract]. From: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, III. Abstract 544.
8. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic. AIDS 1999; 13:F35-F43.
9. Deeks S, Barbour J, Swanson M, et al. Sustained CD4 T cell response after virologic failure of protease inhibitor based regimens [abstract]. From: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, III. Abstract 494.
10. + cell count in HIV-1 infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998; 351:723-724.
11. Carr A, Samaras K, Burton S, Law M, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58.
12. Henry K, Melroe H, Huebesch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351:1328.
13. Brinkman K, ter Hofstede HJ, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12:1735-1744.
14. Scribner AN, Skiest DJ, Marcantonio D, et al. A case control study of osteonecrosis in HIV [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1999:1311.
15. Hodak SP, Fluhme D, Kumar P, et al. Avascular necrosis and protease exposure [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy 1999:1312.
16. Paterson D, Swindells S, Mohr J, et al. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMS caps [abstract]. Sixth Conference on Retroviruses and Opportunistic Infections. 1999:92.
17. Kitahata MM, Koepsell TD, Deyo RA, et al. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Eng J Med 1996; 334:701-706.
18. Laine C, Markson LE, McKee LJ, et al. The relationship of clinic experience with advanced HIV and survival of women with AIDS. AIDS 1998; 12:417-424.